ESMO 2019: Liquid biopsy has prognostic role in colorectal cancer and potential for guiding therapy
Liquid biopsy is likely to play an increasing role in identifying patients with colorectal cancer…
Browsing: ESMO 2019
ESMO 2019: More ovarian cancer patients benefit from maintenance combined targeted therapy
New data presented at the ESMO Congress 2019 in Barcelona, Spain, show the benefit of a more…
ESMO 2019: PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that…
ESMO 2019: Two studies show CDK4/6 inhibitors improve overall survival in advanced breast cancer
New data from two studies reported at the ESMO Congress 2019 have shown that treatment with a…
ESMO 2019: DNA profiling may hold key to better treatment options in carcinoma of unknown primary
DNA profiling is revealing novel treatment choices for patients with cancer whose disease has spread…
ESMO 2019: New combination therapy offers bowel cancer patients extra treatment option
Based on scientific findings of the Netherlands Cancer Institute a new combination treatment has been…
ESMO 2019: Mesothelioma trial suggests immunotherapy as an alternative to chemotherapy
Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may…
ESMO 2019: Blood test can replace invasive biopsy for more patients with lung cancer
A growing number of patients with advanced lung cancer could soon be offered a blood…
ESMO 2019: Adding immunotherapy to chemotherapy prolongs progression free survival in bladder cancer
Patients with metastatic urothelial cancer have longer progression free survival when treated with first-line immunotherapy…
ESMO 2019: First targeted therapy for cholangiocarcinoma shows clinical benefit in phase III trial
New data have shown for the first time that targeted therapy can improve the outcome…